RMD vs COO — Key Metrics
| Metric | RMD (RESMED INC) | COO (COOPER COMPANIES INC) |
|---|---|---|
| Price | 242.61 | 60.75 |
| Market Cap | 34.12 Billion | 11.55 Billion |
| P/E (TTM) | 22.04 | 20.66 |
| P/B (Quarterly) | 5.438 | 1.449 |
| P/S (TTM) | 5.95 | 2.73 |
| Net Profit Margin (TTM) | 27.8 | 13.5 |
| Gross Margin (TTM) | 61.1 | 65.9 |
| ROE (TTM) | 25.1 | 6.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Underperform
Recommendation Summary
Stock RMD is projected to outperform the market, stock COO is projected to underperform the market. Upfront Recommendation: RMD.
Financial Metrics
| RMD | Metrics | COO |
|---|---|---|
| $242.61 | Price | $60.75 |
| — | Market Capitalization | — |
| 22.04 | Price to Earnings Ratio | 20.66 |
| 5.95 | Price to Sales | 2.73 |
| 21.21 | Price to FCF Ratio | 17.04 |
| 9.75 | Price to Gross Profit | 4.14 |
| 86.65 | Price to R&D | 68.03 |
| 9.73 | Price to Current Assets | 5.06 |
RMD vs COO at a glance
Resmed INC (RMD) and Cooper Companies INC (COO) are both Medical Instruments & Supplies companies in the Healthcare sector. RMD is the larger, at $34.1 billion in market value against $11.6 billion for COO, about 3.0 times the size.
On trailing-twelve-month figures, RMD trades at 22.0 times trailing earnings and COO at 20.7; net profit margins are 27.8% and 13.5%.
The Upfront Investment model currently rates RMD Outperform and COO Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.